Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Regulation FD Disclosure
Item 7.01.
Regulation FD Disclosure
On April 2, 2019, Natus Medical Incorporated, a Delaware corporation (“Natus” or the “Company”) issued a press release (the “Press Release”) announcing that it has signed an agreement to sell its wholly-owned subsidiary, Medix Medical Devices, SRL (“Medix”) in an employee led buyout. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information included in this Current Report on Form 8-K to Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.
|
Item 7.01. |
Financial Statements and Exhibits |
(d) Exhibits.
|
ExhibitNo. |
Description |
|
99.1 |
Press release dated April 2, 2019. |
NATUS MEDICAL INC Exhibit
EX-99.1 2 a2019-04x02saleofmedixbusi.htm EXHIBIT 99.1 Exhibit Natus Announces Sale of Medix Business“Local Management to acquire the stock of Natus’ Argentinian subsidiary”PLEASANTON,…
To view the full exhibit click here
About Natus Medical Incorporated (NASDAQ:BABY)
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.
